Trial for the drug CT900 which targets ovarian cancer cells expanded into a larger trial

11 October 2018

A trial for the drug CT900 (previously called ONX-0801) which targets ovarian cancer cells via a protein called the alpha-folate receptor is being expanded into a larger trial.

The drug could be suitable for women with ovarian cancer for whom chemotherapy has failed, and whose tumours have high levels of the alpha-folate receptor on the surface of cancer cells..

Comments (0)

Please verify your action

Comment (maximum 3500 characters) (required)

Add a picture

Notify me when someone makes a comment

First name (required)

Last name (required)

Email (required)

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Keeping In Touch

We would love to keep you posted with news, activities and how you can help in other ways. We'll never sell or swap your details with anybody else. You are free to change your mind at any time. Please tick the boxes below to opt in to receive communications from Ovacome by email, SMS, telephone, and/or post.

Via email

Via telephone

Via SMS

Via post

Which country do you live in?

Postcode (required)

Address line 1

Address line 2

Town or city

Your Privacy

We will always store your personal details securely. We'll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy.

By submitting this form you are agreeing to our terms and conditions

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.